AIを使用した治療法の発明：人工知能は発明活動として認められるべきか？
単独発明者として人工知能が指定された特許出願2件が、口頭審理の結果、発明者は人間でなければならないという理由により、欧州特許庁により拒絶されました。機械は真の発明活動を行えるのでしょうか？そうであるなら、結果的な技術の保護にどのような影響があるのでしょうか？
単独発明者として人工知能が指定された特許出願2件が、口頭審理の結果、発明者は人間でなければならないという理由により、欧州特許庁により拒絶されました。機械は真の発明活動を行えるのでしょうか？そうであるなら、結果的な技術の保護にどのような影響があるのでしょうか？
Read More
Enablement and Plausibility – is a guess good enough?
The Australian enablement requirement was introduced with the IP Laws Amendment (Raising the Bar) Act 2012 that came into effect on 15 April 2013. However, some seven years later...
The Australian enablement requirement was introduced with the IP Laws Amendment (Raising the Bar) Act 2012 that came into...
Read More
Coronavirus the global pandemic: a guide to patenting
COVID-19 (short for coronavirus disease 2019) is caused by Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), more commonly referred to as coronavirus. Coronavirus has dominated world headlines in 2020, leading to nationwide...
COVID-19 (short for coronavirus disease 2019) is caused by Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), more commonly referred to...
Read More
Ramsay Health Care Investments Pty Limited [2020] ATMO 11 (30 January 2020)
Ramsay Health Care Investments Pty Limited (“Ramsay”) applied under Australian Trade Mark Application No. 1790252 to register the RAMSAY PHARMACY trade mark in respect of retailing services in Class 35 and pharmacy...
Ramsay Health Care Investments Pty Limited (“Ramsay”) applied under Australian Trade Mark Application No. 1790252 to register the RAMSAY PHARMACY trade...
Read More
Co-pack causes patent term extension problems for Patentee
Pharma Mar S.A. applied for a patent term extension (PTE) for their Australian patent 754073 on the basis of the listing on the Australian Register of Therapeutic Goods (ARTG) of the...
Pharma Mar S.A. applied for a patent term extension (PTE) for their Australian patent 754073 on the basis of the...
Read More
医療使用クレームの侵害への入り交じったメッセージおよび成功予測への数の付与
Mylan Health Pty Ltd (formerly BGP Products Pty Ltd) v Sun Pharma ANZ Pty Ltd (formerly Ranbaxy Australia Pty Ltd) FCA 28 (『 Mylan v Sun Pharma』) は薬物フェノフィブラートに関する3件の特許についての裁判事件です。フェノフィブラートは特に糖尿病患者において異常血中脂質を治療するために使用される医薬品です。これら特許のうち１件（オーストラリア特許第2006313711号、『711号特許』）は糖尿病性網膜症を治療するためのフェノフィブラートの使用に関し、他の2件の特許（豪州特許第731964号、『964号特許』および豪州特許第2003301807号（『807号特許』）はフェノフィブラートの組成物および製剤に関します。
Mylan Health Pty Ltd (formerly BGP Products Pty Ltd) v Sun Pharma ANZ Pty Ltd (formerly Ranbaxy Australia Pty...
Read More
Invention ownership and patents: the importance of written agreements
Patent rights for an invention can be challenged if ownership is not 'rock-solid'. Written agreements play an important role in determining ownership and patent rights to an invention, and use of the...
Patent rights for an invention can be challenged if ownership is not 'rock-solid'. Written agreements play an important role in determining...
Read More
Conference poster presentations as prior art for the assessment of novelty of a later patent application
Conferences are an important way for scientists and researchers to share and promote their research. They typically include poster presentation sessions where researchers present their findings. Conferences help generate interest in the scientific community...
Conferences are an important way for scientists and researchers to share and promote their research. They typically include poster presentation sessions...
Read More